A recently published phase I clinical trial of autologous CD5 CAR-T cells (NCT03081910) targeting relapsed/refractory T cell lymphomas has shown a tolerable safety profile, with no patient experiencing CRS of grade 3 or higher [133]. The gene discussed is CD5; the disease is T-cell non-Hodgkin lymphoma.